Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

RED BOOK PRICE DATA EXCLUDED FROM ADVERTISING SOLICITATION

Executive Summary

RED BOOK PRICE DATA EXCLUDED FROM ADVERTISING SOLICITATION, William Reynolds, publisher of Drug Topics Red Book asserted in Nov. 11 letters to the American Society of Hospital Pharmacists (ASHP) and the National Wholesale Druggists' Association (NWDA). Reynolds maintained that, although "ads are placed in the publication," the Red Book collects price information "on its own, from manufacturers, wholesalers and other suppliers." Reynolds wrote ASHP Executive VP Joseph Oddis and NWDA President Charles Trefrey to clarify statements the associations made about Red Book listings in their comments to the Health Care Financing Administration (HCFA) on Medicaid Rx drug reimbursement reform ("The Pink Sheet" Nov. 3, p. 7). ASHP stated in Oct. 20 comments to HCFA that "manufacturers pay the publishers to advertise their products in Red Book/Blue Book, which makes it suspect as an objective source." In the context of its objections that Red Book listings may imply, but do not assure, adequate inventory, NWDA referred to "firm advertising" in the publications. Reynolds protested that such statements "convey the misinformation that the price listings in Red Book are paid for by advertisers." Price information is included in Red Book "at no charge to the manufacturer" and is independent of any product advertisements the manufacturer may choose to run in the publication. According to Laszlo Schaffer, general manager of Red Book's data base services, the company solicits price and product information on an "ongoing basis" by written, telephone and electronic communication. Annually, in the latter part of the summer, Red Book sends out "product listing verification sheets" to drug firms. Once information is received, Red Book checks the accuracy against "barometers of reality" developed from various industry sources, including wholesaler surveys. In addition to the annual Red Book reference, which includes more than 175,000 product listings, for the past several years Red Book has produced monthly update publications and electronic tapes. The Red Book Update provides specifics on the 2,500 leading Rx products, 1,500 OTCs and new products. Data is entered daily, or when received, on the electronic tapes, which are available to various third-party payors, insurance companies and health and welfare programs. Schaffer added that this year the Red Book data base services division is in the "midst of an aggressive systems enhancement on the electronic side." The project, he said, "will create the ability to do some in-depth research and analysis and comparative analysis," adding: "It will give us alot more tools to work with to ascertain drug quality therapeutic information, generic information and more detailed ways of quickly retrieving data and making it available to the general public and to our electronic users."

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth

Latest Headlines
See All
UsernamePublicRestriction

Register

PS011045

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel